Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103350
Status:
COMPLETED
Last Update Posted:
2008-05-20
First Post:
2005-02-07
Brief Title:
Safety of TG100-115 for Heart Attack Treated With Angioplasty
Sponsor:
TargeGen
Organization:
TargeGen
Study Overview
Official Title:
A Phase 1-2 Multicenter Randomized Double-Blind Placebo Controlled Prospective Study to Evaluate the Safety and Potential Efficacy of Single Increasing Doses of TG100-115 in Subjects Undergoing Percutaneous Coronary Intervention for Acute Anterior ST Elevation Myocardial Infarction
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
TG100-115 is able to reduce the size of heart attacks in pre-clinical models The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow We will also evaluate whether TG100-115 reduces heart muscle damage
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None